Immix Biopharma (IMMX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Immix Biopharma (IMMX) is Neutral.

The composite score behind that read is -0.15, weighing +0.05 of bullish evidence against -0.25 bearish.

Immix Biopharma last closed at $10.13, +4.65% on the session.

Against the IVW growth benchmark the position is +3.73% over the forecast window.

The read is built from 11 underlying insights — 4 bullish and 7 bearish.

Agreement across those insights is 64%.

Immix Biopharma has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Immix Biopharma in the 21st percentile on return on equity, where 100 is best.

Immix Biopharma is classified under Health Care / Biotechnology, with a market capitalisation of $802.46M.

StockMap tracks Immix Biopharma as the 136th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Immix Biopharma ranks 113th of 344 in the group, against a group median of -0.21.